Donington and Stiles Summarize NSCLC Resectability Parameters and Multidisciplinary Management
January 8th 2024Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, definitions of resectability, and the incorporation of new multidisciplinary management guidance.
Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions
December 11th 2023Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the potential surgical implications of the ALINA trial with adjuvant alectinib, and the importance of early-stage molecular testing in lung cancer.
Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation Dermatitis
October 9th 2023Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.
Thoracic Clinical Expert Looks at Optimal Ways to Translate Data Into Practice
September 20th 2023As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.
Optimizing the Selection of Novel Therapy for Patients With Advanced NSCLC
Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.
Advanced NSCLC: Interpreting Data From the POSEIDON Trial
A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.
Role for IO Therapy in Advanced NSCLC With Concomitant KRAS and KEAP1/STK11 Mutations
Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.
Combination Chemo + IO Therapy in Advanced Non–Small Cell Lung Cancer
A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.
Selecting Therapy for Advanced NSCLC Based on PD-L1 and NGS Testing
Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.
Factors in Selecting IO Therapy for Patients With Advanced NSCLC
Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.
Adjuvant Treatment Strategies in Resectable Non–Small Cell Lung Cancer
Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.
Key Decisionmaking Factors in Resectable Non–Small Cell Lung Cancer
Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).
BRONx-CAN Program Aims to Deliver the Best Cancer Treatments Early
December 1st 2022Montefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.
Halmos Highlights Immunotherapy Treatment Decisions, Emerging ADCs in NSCLC
Balazs Halmos, MD, discusses the role of immunotherapy in the frontline setting of NSCLC and the emerging pipeline of antibody-drug conjugates that could affect the treatment paradigm in lung cancer.